Standard of Care for Relapsed Refractory Multiple Myeloma
Research type
Research Study
Full title
A Prospective, Multinational Study of Real-Life Current Standards of Care in patients with Relapsed and/or Refractory Multiple Myeloma
IRAS ID
306507
Contact name
David Wright
Contact email
Sponsor organisation
Janssen-Cilag International N.V
Duration of Study in the UK
2 years, 10 months, 28 days
Research summary
The introduction of new treatments over the last two decades has improved survival outcomes in patients with multiple myeloma (MM). However, despite therapeutic advances, most patients with MM eventually relapse and/or become refractory to treatment, there remains an incomplete understanding of how treatment of patients with relapsed/refractory multiple myeloma (RRMM) is evolving in routine clinical practice and the effectiveness of those treatments, given the availability of new treatment options, such as B-cell maturation antigen (BCMA) targeted agents.
The purpose of this prospective, non-interventional, multinational study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety of current SOC antimyeloma treatments in participants with previously treated multiple myeloma.
REC name
Wales REC 6
REC reference
21/WA/0349
Date of REC Opinion
22 Oct 2021
REC opinion
Favourable Opinion